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Staphylococcus aureus (S. aureus) releases in the airway lumen virulence factors
(VF) that may impair the functionality of airway epithelium. The aim of our study
was to determine whether a corticosteroid (ﬂuticasone propionate: FP) combined
with a long-acting b2 adrenergic receptor agonist (salmeterol: Sal) was able to
regulate CFTR localization, ion content and cytokine expression after exposure of
airway glandular cells to S. aureus VF.
A human airway glandular cell line was exposed to 2% S. aureus VF for 1 h and
then incubated with Sal/FP for 4 h. The expression of actin and CFTR proteins was
analyzed by immunoﬂuorecence. Videomicroscopy was used to evaluate chloride
secretion and X-ray microanalysis to measure the intracellular ion and water content.
Pro-inﬂammatory cytokine expression was assessed by RT-PCR and ELISA.
When the cells were incubated with S. aureus VF and then with Sal/FP, CFTR
recovered an apical localization compared to the cytoplasmic localization in cells
incubated with S. aureus VF alone. Sal/FP treatment signiﬁcantly increased the
chloride content (p< 0.05) and decreased the S and K content (p< 0.001 and
p< 0.05, respectively) in the intra-cytoplasmic secretory granules, compared to the
S. aureus VF-treated cells. We also observed that Sal/FP treatment downregulated
S. aureus VF-induced IL-8 and TNFa expression and release.
Our results demonstrate that treatment with the combination of a corticosteroid and
a long-acting b2 adrenergic receptor agonist after bacterial infection may restore
the airway glandular cell functionality.
Supported by: Association Vaincre la Mucoviscidose and GlaxoSmithKline.
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In numerous airway diseases such as cystic ﬁbrosis, the bronchiolar epithelium is
frequently injured and has to regenerate in order to restore its defense functions.
In animal models, it has been proposed that Clara cells could be the bronchiolar
stem cells. In human, we have previously demonstrated that bronchial epithelial
basal cells expressing speciﬁcally CD151 and Tissue Factor (TF) were able to
reconstitute a mucociliary differentiated and functional epithelium and then, could
be considered as, at least progenitor cells of the bronchial epithelium (Hajj et al.,
2007). The aim of our study was to determine the stem/progenitor potential of basal
cells of human bronchiolar epithelium.
Human bronchioles were microdissected from lung pieces obtained from surgery
and processed either for histological examination and immunohistochemical detec-
tion of basal cell markers, or for bronchiolar cells dissociation. After enzymatic
dissociation, bronchiolar epithelial cells were prepared for ﬂow cytometry analysis
of constitutive cell populations. Our results demonstrated that the human bronchiolar
epithelium showed a basal cell layer. Bronchiolar basal cells, expressing speciﬁcally
cytokeratin 13, exhibited a CD151 staining on their plasma membrane. Analysis
by ﬂow cytometry conﬁrmed the CD151 expression by bronchiolar epithelial basal
cells which represented 20 to 30% of the total bronchiolar cells. Based on their
CD151 expression, bronchiolar basal cells will be sorted in order to determine if
they act as progenitor cells during the bronchiolar epithelial regeneration both in
vitro in air-liquid interface cultures, and in vivo in humanized xenografts in nude
mice.
Supported by: Association Vaincre La Mucoviscidose and Re´gion Champagne-
Ardenne.
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In numerous respiratory diseases such as cystic ﬁbrosis, the airway epithelium is
frequently injured and remodelled. It must rapidly regenerate its structure. During
the regeneration process, various molecules are produced by the epithelial cells.
We have previously shown that epithelial IL-8, matrix metalloproteinases (MMP)-7
and -9 and their inhibitor TIMP-1 were modulated during the non-CF regeneration,
MMPs playing a crucial role in epithelial mucociliary differentiation. Moreover, CF
bronchial epithelial regeneration, in absence of infection, gave rise to a remodelled
epithelium and was associated with deregulation of these molecules. The aim of
our study was to determine the expression and secretion of epithelial factors during
processes of remodelling such as squamous metaplasia or goblet cell hyperplasia.
Human airway epithelial cells from nasal polyps were cultured at the air-liquid
interface, and culture conditions were modiﬁed to induce remodelling. Cultures
were collected at different culture steps for immunohistochemical and electrophys-
iological studies. Total RNAs were extracted for RT-PCR, and secreted liquids
collected for bactericidal activity assessment and zymography. Despite remodelled
airway epithelia were able to kill Staphylococcus aureus, their bioelectric properties
were disturbed. We also showed that IL-8, TIMP-1, MMP-7 and -9 mRNA levels,
as well as MMPs activities were modulated during the processes of remodelling.
Our results demonstrate that airway epithelial remodelling leads to altered epithelial
functions and is associated to deregulation of epithelial factors expression. It will
be now important to determine the speciﬁc involvement of deregulated factors in
the genesis of squamous metaplasia and goblet cell hyperplasia.
Supported by: Association Vaincre la Mucoviscidose.
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Cystic ﬁbrosis transmembrane regulator protein (CFTR) transports anions across
apical membranes of epithelial cells; among these anions is glutathione (GSH) a
major antioxidant. Previous studies show a deﬁcit in mitochondrial GSH (mGSH)
in cystic ﬁbrosis (CF) cells. In other cellular models a similar decrease has been
shown to lead to complex I (CI) inhibition. Our aim was to investigate the
possible relationships between mitochondrial GSH and CI activity in CF models.
Mitochondria were isolated from murin colonic epithelia from cftr−/− vs cftr +/+
mice. We also used mitochondria from two epithelial cell lines derived from CF
patients (CFBE Par and IB3) vs their corrected cell lines (CFBE WT and C38,
respectively). GSH was measured by HPLC with electrochemical detection. CI
activity was measured by spectrophometry and native PAGE was used to study
its expression. Our results show a signiﬁcant decrease in CI activity in all three
CF models. Interestingly, we were able to mimic this decrease in corrected cells by
treating them with a CFTR inhibitor (Inh 172). Decrease in CI activity could not be
explained by a decrease in CI expression. Furthermore, no difference in expression
was observed after Inh 172 treatment. mGSH measurements conﬁrmed a decrease
in CF cells vs corrected cells. Using a mitochondrial speciﬁc GSH mono ethyl ester
we were able to restore mGSH levels in CF cells; this allowed partial recovery of
CI activity. Similar results were observed when mitochondria were reduced with
DTT. These results suggest that oxidative modiﬁcations of certain mitochondrial
proteins and possibly CI proteins could be involved in CI inhibition in CF models
and are currently under investigation.
Supported by: Legs Poix.
